{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:33:03Z","timestamp":1793485983537,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Avacopan is effective in ANCA-associated vasculitis (AAV) in randomized trials, and real-world studies have supported its clinical effectiveness. However, treatment-emergent adverse events (TEAEs) often lead to discontinuation, and data beyond 1 year remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively studied 40 adults with newly diagnosed or relapsing AAV treated with avacopan. Patients were classified into continuation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) and discontinuation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) groups according to discontinuation due to avacopan-related TEAEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median follow-up of 29 months (interquartile range 26\u201332), avacopan-related TEAEs occurred in 21 patients (52.5%) at a median of 1.4 months following initiation; all patients in the discontinuation group stopped avacopan because of TEAEs. Clinical remission (BVAS\u2009=\u20090 and no glucocorticoid use) was achieved in 47.5%, 62.5%, and 87.2% of patients at 6, 12, and 24 months, respectively. Five patients (21.7%) in the continuation group remained in remission on avacopan monotherapy for a median of 24 months after withdrawing all other immunosuppressive agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective single-center cohort, clinical outcomes beyond 1 year appeared broadly comparable between patients who continued avacopan and those who discontinued it early because of TEAEs. Further prospective studies are needed to define the optimal use, patient selection, and duration of avacopan therapy in AAV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-026-00655-7","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:33:56Z","timestamp":1779168836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of avacopan beyond the first year in antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study"],"prefix":"10.1186","volume":"10","author":[{"given":"Makoto","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kinashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1056\/nejm199711203372106","volume":"337","author":"JC Jennette","year":"1997","unstructured":"Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512\u201323. https:\/\/doi.org\/10.1056\/nejm199711203372106.","journal-title":"N Engl J Med"},{"key":"655_CR2","first-page":"S11","volume":"33","author":"CGM Kallenberg","year":"2015","unstructured":"Kallenberg CGM. Pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol. 2015;33:S11\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/art.42314","volume":"75","author":"T Kudo","year":"2023","unstructured":"Kudo T, Nakazawa D, Watanabe-Kusunoki K, Kanda M, Shiratori-Aso S, Abe N, et al. Regulation of NETosis and inflammation by cyclophilin D in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2023;75:71\u201383. https:\/\/doi.org\/10.1002\/art.42314.","journal-title":"Arthritis Rheumatol"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1097\/01.asn.0000135058.46193.72","volume":"15","author":"JJ Yang","year":"2004","unstructured":"Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol. 2004;15:2103\u201314. https:\/\/doi.org\/10.1097\/01.asn.0000135058.46193.72.","journal-title":"J Am Soc Nephrol"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"152413","DOI":"10.1016\/j.imbio.2023.152413","volume":"228","author":"J Schanzenbacher","year":"2023","unstructured":"Schanzenbacher J, Hendrika K\u00e4hler K, Mesler E, Marcel Karsten C, Leonard Seiler D. The role of C5a receptors in autoimmunity. Immunobiology. 2023;228:152413. https:\/\/doi.org\/10.1016\/j.imbio.2023.152413.","journal-title":"Immunobiology"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"1261151","DOI":"10.3389\/fimmu.2023.1261151","volume":"14","author":"S Shiratori-Aso","year":"2023","unstructured":"Shiratori-Aso S, Nakazawa D. The involvement of NETs in ANCA-associated vasculitis. Front Immunol. 2023;14:1261151. https:\/\/doi.org\/10.3389\/fimmu.2023.1261151.","journal-title":"Front Immunol"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/nejmoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332. https:\/\/doi.org\/10.1056\/nejmoa0909905.","journal-title":"N Engl J Med"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386.","journal-title":"N Engl J Med"},{"issue":"2","key":"655_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/mr\/roac037","volume":"33","author":"M Harigai","year":"2023","unstructured":"Harigai M, Kaname S, Tamura N, Dobashi H, Kubono S, Yoshida T. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: a subanalysis of a randomized phase 3 study. Mod Rheumatol. 2023;33(2):338\u201345. https:\/\/doi.org\/10.1093\/mr\/roac037.","journal-title":"Mod Rheumatol"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41927-025-00456-4","volume":"9","author":"R Tagami","year":"2025","unstructured":"Tagami R, Yamaguchi M, Sugiyama H, Kinashi H, Imai K, Kamiya K, et al. Real-world effectiveness and safety of avacopan in AAV. BMC Rheumatol. 2025;9:8. https:\/\/doi.org\/10.1186\/s41927-025-00456-4.","journal-title":"BMC Rheumatol"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s41927-025-00555-2","volume":"9","author":"Y Ushio","year":"2025","unstructured":"Ushio Y, Shimada H, Wakiya R, Nakashima S, Miyagi T, Sugihara K, et al. Avacopan is effective in inducing remission for MPA\/GPA, regardless of changes in serum C5a levels: a single-center study in Japan. BMC Rheumatol. 2025;9:99. https:\/\/doi.org\/10.1186\/s41927-025-00555-2.","journal-title":"BMC Rheumatol"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","volume":"9","author":"R Zonozi","year":"2024","unstructured":"Zonozi R, Aqeel F, Le D, Cortazar FB, Thaker J, Zabala Ramirez MJ, et al. Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int Rep. 2024;9:1783\u201391. https:\/\/doi.org\/10.1016\/j.ekir.2024.03.022.","journal-title":"Kidney Int Rep"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.ekir.2024.07.007","volume":"9","author":"J Zimmermann","year":"2024","unstructured":"Zimmermann J, Sonnemann J, Jabs WJ, Sch\u00f6nermarck U, Vielhauer V, Bieringer M, et al. Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting. Kidney Int Rep. 2024;9:2803\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2024.07.007.","journal-title":"Kidney Int Rep"},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/rheumatology\/keae534","volume":"64","author":"J Draibe","year":"2025","unstructured":"Draibe J, Espigol-Frigol\u00e9 G, Cid MC, Prados MC, Guill\u00e9n E, Villacorta J, et al. The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. Rheumatology (Oxford). 2025;64:2019\u201326. https:\/\/doi.org\/10.1093\/rheumatology\/keae534.","journal-title":"Rheumatology (Oxford)"},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/rheumatology\/keae359","volume":"64","author":"C Gabilan","year":"2025","unstructured":"Gabilan C, Belliere J, Moranne O, Pfirmann P, Samson M, Delattre V, et al. Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study. Rheumatology (Oxford). 2025;64:2214\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keae359.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"655_CR16","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.ekir.2025.103753","volume":"11","author":"I Berke","year":"2025","unstructured":"Berke I, Keller F, Untersulzner C, Shin JI, Park PG, Oh SS, Callemeyn J, Kronbichler A. Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice. Kidney Int Rep. 2025;11(4):103753. https:\/\/doi.org\/10.1016\/j.ekir.2025.103753.","journal-title":"Kidney Int Rep"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","volume":"63","author":"S Yamaguchi","year":"2024","unstructured":"Yamaguchi S, Yamazaki M, Kido T, Hounoki H, Muraishi N, Tajiri K, et al. A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford). 2024;63:e120\u20132. https:\/\/doi.org\/10.1093\/rheumatology\/kead285.","journal-title":"Rheumatology (Oxford)"},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","volume":"63","author":"K Kojima","year":"2024","unstructured":"Kojima K, Fukui S, Tanigawa M, Sumiyoshi R, Koga T, Shimakura A, et al. Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan. Rheumatology (Oxford). 2024;63:e101\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/kead509.","journal-title":"Rheumatology (Oxford)"},{"key":"655_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222\u20137. https:\/\/doi.org\/10.1136\/ard.2006.054593.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"655_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/ard.2005.051078","volume":"66","author":"O Flossmann","year":"2007","unstructured":"Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66(3):283\u201392. https:\/\/doi.org\/10.1136\/ard.2005.051078.","journal-title":"Ann Rheum Dis"},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"655_CR22","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/S2665-9913(24)00025-0","volume":"6","author":"S Arnold","year":"2024","unstructured":"Arnold S, Kitching AR, Witko-Sarsat V, et al. Myeloperoxidase-specific antineutrophil cytoplasmic antibody-associated vasculitis. Lancet Rheumatol. 2024;6(5):e300\u201313. https:\/\/doi.org\/10.1016\/S2665-9913(24)00025-0.","journal-title":"Lancet Rheumatol"},{"key":"655_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.13498","volume":"202","author":"S Moiseev","year":"2020","unstructured":"Moiseev S, Lee JM, Zykova A, Bulanov N, Novikov P, Gitel E, et al. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. Clin Exp Immunol. 2020;202:394\u2013402. https:\/\/doi.org\/10.1111\/cei.13498.","journal-title":"Clin Exp Immunol"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s13730-023-00841-3","volume":"13","author":"H Miyake","year":"2024","unstructured":"Miyake H, Tanabe K, Yamaji S, Kihara T. Early transition to avacopan from glucocorticoids applied during induction therapy for microscopic polyangiitis with rapidly progressive glomerulonephritis. CEN Case Rep. 2024;13:277\u201383. https:\/\/doi.org\/10.1007\/s13730-023-00841-3.","journal-title":"CEN Case Rep"},{"key":"655_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"key":"655_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2023-224489","volume":"83","author":"R Zonozi","year":"2024","unstructured":"Zonozi R, Cortazar FB, Jeyabalan A, Sauvage G, Nithagon P, Huizenga NR, et al. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: A randomised trial. Ann Rheum Dis. 2024;83:351\u20139. https:\/\/doi.org\/10.1136\/ard-2023-224489.","journal-title":"Ann Rheum Dis"},{"key":"655_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/ndt\/gfad237","volume":"39","author":"A Chalkia","year":"2024","unstructured":"Chalkia A, Jayne D. ANCA-associated vasculitis\u2014treatment standard. Nephrol Dial Transpl. 2024;39:944\u201355. https:\/\/doi.org\/10.1093\/ndt\/gfad237.","journal-title":"Nephrol Dial Transpl"},{"key":"655_CR28","doi-asserted-by":"publisher","first-page":"103438","DOI":"10.1016\/j.autrev.2023.103438","volume":"23","author":"D Roccatello","year":"2024","unstructured":"Roccatello D, Padoan R, Sciascia S, Iorio L, Nic An R\u00edogh E, Little MA. Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis? Autoimmun Rev. 2024;23:103438. https:\/\/doi.org\/10.1016\/j.autrev.2023.103438.","journal-title":"Autoimmun Rev"},{"key":"655_CR29","doi-asserted-by":"publisher","first-page":"1655326","DOI":"10.3389\/fimmu.2025.1655326","volume":"16","author":"F Alberici","year":"2025","unstructured":"Alberici F, Flossmann O, Lamprecht P, Loudon KW, Padoan R, Popov T, et al. Antineutrophil cytoplasmic antibody-associated vasculitis: insights into relapse risk and future management directions. Front Immunol. 2025;16:1655326. https:\/\/doi.org\/10.3389\/fimmu.2025.1655326.","journal-title":"Front Immunol"},{"key":"655_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13730-024-00910-1","volume":"14","author":"Y Ubara","year":"2025","unstructured":"Ubara Y, Oba Y, Kurihara S, Sekine A, Yamanouchi M, Hasegawa E, et al. A case of renal limited myeloperoxidase anti-neutrophil cytoplasmic antibody-positive vasculitis treated with maintenance avacopan monotherapy. CEN Case Rep. 2025;14:85\u20139. https:\/\/doi.org\/10.1007\/s13730-024-00910-1.","journal-title":"CEN Case Rep"},{"key":"655_CR31","doi-asserted-by":"publisher","first-page":"rkae100","DOI":"10.1093\/rap\/rkae100","volume":"8","author":"S Kubota","year":"2024","unstructured":"Kubota S, Hanai S, Tanaka-Mabuchi N, Ito R, Nakagomi D. Is it possible to use avacopan alone in the induction of remission in ANCA-associated vasculitis? Rheumatol Adv Pract. 2024;8:rkae100. https:\/\/doi.org\/10.1093\/rap\/rkae100.","journal-title":"Rheumatol Adv Pract"},{"issue":"7","key":"655_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2169\/internalmedicine.6273-25","volume":"65","author":"E Hishida","year":"2026","unstructured":"Hishida E, Nagata D. Avacopan-associated Liver Injury in Japanese Patients with ANCA-associated Vasculitis: Clinical, Genetic, and Mechanistic Perspectives. Intern Med. 2026;65(7):941\u20132. https:\/\/doi.org\/10.2169\/internalmedicine.6273-25.","journal-title":"Intern Med"},{"key":"655_CR33","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1093\/rheumatology\/keae689","volume":"64","author":"K Mori","year":"2025","unstructured":"Mori K, Shirai T, Mutoh T, Inoue J, Fujishima F, Kubo S, et al. Drug-induced liver injury related to avacopan therapy. Rheumatology. 2025;64:2533\u201340. https:\/\/doi.org\/10.1093\/rheumatology\/keae689.","journal-title":"Rheumatology"},{"key":"655_CR34","doi-asserted-by":"publisher","first-page":"e42121","DOI":"10.1097\/MD.0000000000042121","volume":"104","author":"R Yamashita","year":"2025","unstructured":"Yamashita R, Izumi Y, Takane K, Kinoshita A, Hiramoto J. Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: A case report. Med (Baltim). 2025;104:e42121. https:\/\/doi.org\/10.1097\/MD.0000000000042121.","journal-title":"Med (Baltim)"},{"key":"655_CR35","doi-asserted-by":"publisher","first-page":"1654735","DOI":"10.3389\/fimmu.2025.1654735","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Meng A, Wang Y. The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis. Front Immunol. 2025;16:1654735. https:\/\/doi.org\/10.3389\/fimmu.2025.1654735.","journal-title":"Front Immunol"},{"key":"655_CR36","doi-asserted-by":"publisher","first-page":"e70194","DOI":"10.1002\/prp2.70194","volume":"13","author":"G Liang","year":"2025","unstructured":"Liang G, Liu X, Gao M, Yang B, Song Y, Liu Q. A real-world disproportionality analysis of avacopan in anti-neutrophil cytoplasmic antibodies associated vasculitis: insights from FDA adverse event reporting system. Pharmacol Res Perspect. 2025;13:e70194. https:\/\/doi.org\/10.1002\/prp2.70194.","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"655_CR37","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1084\/jem.20030374","volume":"198","author":"CW Strey","year":"2003","unstructured":"Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003;198(6):913\u201323. https:\/\/doi.org\/10.1084\/jem.20030374.","journal-title":"J Exp Med"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00655-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00655-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00655-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:35:25Z","timestamp":1783647325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00655-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00655-7","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Aichi Medical University (approval no. 2019-H151) and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}